269 related articles for article (PubMed ID: 25573098)
1. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
Jiang H; Wang H; Wang S; Pei Z; Fu Z; Fang C; Wang J; Lu Q; Wang E; Li J
Mol Med Rep; 2015 May; 11(5):3523-32. PubMed ID: 25573098
[TBL] [Abstract][Full Text] [Related]
2. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer.
Han Y; Wang XB; Xiao N; Liu ZD
Asian Pac J Cancer Prev; 2013; 14(5):2987-90. PubMed ID: 23803067
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer.
Cao Y; Zhang G; Wang P; Zhou J; Gan W; Song Y; Huang L; Zhang Y; Luo G; Gong J; Zhang L
BMC Gastroenterol; 2017 Jan; 17(1):2. PubMed ID: 28056823
[TBL] [Abstract][Full Text] [Related]
4. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
[TBL] [Abstract][Full Text] [Related]
5. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the mRNA expression of
Sun S; Shi W; Wu Z; Zhang G; Yang BO; Jiao S
Exp Ther Med; 2015 Sep; 10(3):937-941. PubMed ID: 26622418
[TBL] [Abstract][Full Text] [Related]
7. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
Kotoula V; Krikelis D; Karavasilis V; Koletsa T; Eleftheraki AG; Televantou D; Christodoulou C; Dimoudis S; Korantzis I; Pectasides D; Syrigos KN; Kosmidis PA; Fountzilas G
BMC Cancer; 2012 Aug; 12():342. PubMed ID: 22866924
[TBL] [Abstract][Full Text] [Related]
8. Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, β-tubulin III, thymidylate synthetase, and topoisomerase IIα in breast cancer: Association with clinicopathological characteristics.
Li J; Sun P; Huang T; He S; Li L; Xue G
Medicine (Baltimore); 2021 Apr; 100(14):e25344. PubMed ID: 33832110
[TBL] [Abstract][Full Text] [Related]
9. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
Shi Y; Chen L; Li J; Lü YL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
[TBL] [Abstract][Full Text] [Related]
10. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy.
Zou ZQ; Du YY; Sui G; Xu SN
Asian Pac J Cancer Prev; 2015; 16(8):3189-94. PubMed ID: 25921119
[TBL] [Abstract][Full Text] [Related]
11. Expression of ERCC1, RRM1, TUBB3 in correlation with apoptosis repressor ARC, DNA mismatch repair proteins and p53 in liver metastasis of colorectal cancer.
Tóth C; Sükösd F; Valicsek E; Herpel E; Schirmacher P; Renner M; Mader C; Tiszlavicz L; Kriegsmann J
Int J Mol Med; 2017 Nov; 40(5):1457-1465. PubMed ID: 28949378
[TBL] [Abstract][Full Text] [Related]
12. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.
Vilmar A; Garcia-Foncillas J; Huarriz M; Santoni-Rugiu E; Sorensen JB
Lung Cancer; 2012 Mar; 75(3):306-12. PubMed ID: 21996087
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiles of ERCC1, TYMS, RRM1, TUBB3 and EGFR in tumor tissue from non-small cell lung cancer patients.
Yu D; Li J; Han Y; Liu S; Xiao N; Li Y; Sun X; Liu Z
Chin Med J (Engl); 2014; 127(8):1464-8. PubMed ID: 24762590
[TBL] [Abstract][Full Text] [Related]
15. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.
Deng LL; Deng HB; Lu CL; Guo Y; Wang D; Yan CH; Lv X; Shao YX
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2097-105. PubMed ID: 24994038
[TBL] [Abstract][Full Text] [Related]
16. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
Lee HW; Choi YW; Han JH; Kim JH; Jung JH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS
Lung Cancer; 2009 Sep; 65(3):377-82. PubMed ID: 19150580
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Leng XF; Chen MW; Xian L; Dai L; Ma GY; Li MH
J Exp Clin Cancer Res; 2012 Mar; 31(1):25. PubMed ID: 22439756
[TBL] [Abstract][Full Text] [Related]
18. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702
[TBL] [Abstract][Full Text] [Related]
19. Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Grossi F; Dal Bello MG; Salvi S; Puzone R; Pfeffer U; Fontana V; Alama A; Rijavec E; Barletta G; Genova C; Sini C; Ratto GB; Taviani M; Truini M; Merlo DF
Dis Markers; 2015; 2015():302649. PubMed ID: 26663950
[TBL] [Abstract][Full Text] [Related]
20. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
